Drugs / FRalphaDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05920798 | Sep 2023 → Jun 2028 expected | fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma +5 | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRalphaDC | “FRalphaDC is a dendritic cell vaccine” NCT05920798 ↗ |
| Action | Deplete | “recognize and destroy the tumor cells by targeting the FRalpha protein” NCT05920798 ↗ |
| Modality | Vaccine | “FRalphaDC is a dendritic cell vaccine” NCT05920798 ↗ |